Antitumor effects of hsa‑miR661‑3p on non‑small cell lung cancer in vivo and in vitro

Lu,Jingjing; Gu,Xia; Liu,Fanglei; Rui,Zhuanghua; Liu,Ming; Zhao,Liming

doi:10.3892/or.2019.7084

Antitumor effects of hsa‑miR661‑3p on non‑small cell lung cancer in vivo and in vitro

Authors:
- Jingjing Lu
- Xia Gu
- Fanglei Liu
- Zhuanghua Rui
- Ming Liu
- Liming Zhao
View Affiliations

Affiliations: Department of Respiratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, Pudong, Shanghai 200120, P.R. China, Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Yangpu, Shanghai 200082, P.R. China
Published online on: March 21, 2019 https://doi.org/10.3892/or.2019.7084
Pages: 2987-2996

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common and lethal cancer worldwide, especially in developing countries. Non‑small cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer. In aprevious study, the protein expression of ubiquitin conjugating enzyme E2 C (UBE2C/UbcH10) in NSCLC tissues and cells was found to be significantly higher than that in adjacent tissues and normal lung epithelial cells. Further study revealed that the aberrant expression of UbcH10 in NSCLC tumors or cancer cells was caused by inactivation of the post‑transcriptional regulation mechanism, and thus microRNAs (miRNAs) may play an important. In the present study, it was demonstrated that the expression of microRNA, hsa‑miR661‑3p, was downregulated and UbcH10 was upregulated in 12 pairs of NSCLC tumors and three NSCLC cell lines. A reporter gene assay revealed that overexpression of hsa‑miR661‑3p effectively reduced the activity of luciferase expressed by a vector bearing the 3' untranslated region of UbcH10 mRNA. Ectopic hsa‑miR661‑3p overexpression mediated by lentiviral infection decreased the expression of UbcH10. Infection of Lv‑miR661‑3p inhibited cell growth and invasion in A549 and SK‑MES‑1 cells. Mechanistically, hsa‑miR661‑3p induced cell cycle G2 arrest through regulation of spindle assembly checkpoint (SAC) function. On the basis of the proposed mechanisms, the objective of the study was to inhibit the proliferation of A549 and SK‑MES‑1 by expressing hsa‑miR661‑3p in vivo and in vitro. Collectively, our results indicated that downregulation of hsa‑miR661‑3p was involved in NSCLC and restoration of hsa‑miR661‑3p impaired the growth of NSCLC cell lines A549 and SK‑MES‑1, suggesting that hsa‑miR661‑3p may be a potential target molecule for the therapy of NSCLC.

View Figures

View References

1	Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature. 411:366–374. 2001. View Article : Google Scholar : PubMed/NCBI
2	Blagosklonny MV and Pardee AB: Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 61:4301–4305. 2001.PubMed/NCBI
3	Berlingieri MT, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A, Mansueto G, Borbone E, Guerriero E, Troncone G and Fusco A: UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer. 43:2729–2735. 2007. View Article : Google Scholar : PubMed/NCBI
4	Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, Ferraro A, Leone V, Sboner A, Barbareschi M, et al: UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 26:2136–2140. 2007. View Article : Google Scholar : PubMed/NCBI
5	Troncone G, Guerriero E, Pallante P, Berlingieri MT, Ferraro A, Del Vecchio L, Gorrese M, Mariotti E, Iaccarino A, et al: UbcH10 expression in human lymphomas. Histopathology. 54:731–740. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, Inoue H, Kuwano H and Mori M: Identification of over expressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 121:33–38. 2007. View Article : Google Scholar : PubMed/NCBI
7	Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M and Nakagawara A: UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 63:4167–4173. 2003.PubMed/NCBI
8	Zhao L, Jiang L, Wang L, He J, Yu H, Sun G, Chen J, Xiu Q and Li B: UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer. J Cancer Res Clin Oncol. 138:1951–1961. 2012. View Article : Google Scholar : PubMed/NCBI
9	Carmichael JA, Wing-San Mak D and O'Brien MA: Review of recent advances in the treatment of elderly and poor performance NSCLC. Cancers (Basel). 10:E2362018. View Article : Google Scholar : PubMed/NCBI
10	Sharma N and Graziano S: Overview of the LUX-lung clinical trial program of afatinib for non-small cell lung cancer. Cancer Treat Rev. 69:143–151. 2018. View Article : Google Scholar : PubMed/NCBI
11	Bassanelli M, Sioletic S, Martini M, Giacinti S, Viterbo A, Staddon A, Liberati F and Ceribelli A: Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. Anticancer Res. 38:3789–3796. 2018. View Article : Google Scholar : PubMed/NCBI
12	Rubin H: Cancer development: The rise of epigenetics. Eur J Cancer. 28:1–2. 1992. View Article : Google Scholar : PubMed/NCBI
13	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
14	Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A, Tsao MS, Iovanna JL, Jurisicova A, Melino G and Mak TW: TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci USA. 106:797–802. 2009. View Article : Google Scholar : PubMed/NCBI
15	van Ree JH, Jeganathan KB, Malureanu L and van Deursen JM: Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol. 188:83–100. 2010. View Article : Google Scholar : PubMed/NCBI
16	Draviam VM, Xie S and Sorger PK: Chromosome segregation and genomic stability. Curr Opin Genet Dev. 14:120–125. 2004. View Article : Google Scholar : PubMed/NCBI
17	Nasmyth K, Peters JM and Uhlmann F: Splitting the chromosome: Cutting the ties that bind sister chromatids. Science. 288:1379–1385. 2000. View Article : Google Scholar : PubMed/NCBI
18	Hu L, Liu X, Chervona Y, Yang F, Tang MS, Darzynkiewicz Z and Dai W: Chromium induces chromosomal instability, which is partly due to deregulation of BubR1 and Emi1, two APC/C inhibitors. Cell Cycle. 10:2373–2379. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kondo S and Kaji M: Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer. 74:124–131. 2011. View Article : Google Scholar : PubMed/NCBI
20	Doherty FJ, Dawson S and Mayer RJ: The ubiquitin-proteasome pathway of intracellular proteolysis. Essays Biochem. 38:51–63. 2002. View Article : Google Scholar : PubMed/NCBI
21	Summers MK, Pan B, Mukhyala K and Jackson PK: The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Mol Cell. 31:544–556. 2008. View Article : Google Scholar : PubMed/NCBI
22	Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, Einav U, Gilad S, Hurban P, Karov Y, et al: MicroRNA expression detected by oligonucleotide microarrays: System establishment and expression profiling in human tissues. Genome Res. 14:2486–2494. 2004. View Article : Google Scholar : PubMed/NCBI
23	Lai EC, Tomancak P, Williams RW and Rubin GM: Computational identification of Drosophila microRNA genes. Genome Biol. 4:R422003. View Article : Google Scholar : PubMed/NCBI
24	Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM and Athey BD: New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res. 19:1175–1183. 2009. View Article : Google Scholar : PubMed/NCBI
25	Gilad S, Lithwick-Yanai G, Barshack I, Benjamin S, Krivitsky I, Edmonston TB, Bibbo M, Thurm C, Horowitz L, Huang Y, et al: Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J Mol Diagn. 14:510–517. 2012. View Article : Google Scholar : PubMed/NCBI
26	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
27	Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, et al: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 16:430–441. 2010. View Article : Google Scholar : PubMed/NCBI
28	Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, et al: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 27:2030–2037. 2009. View Article : Google Scholar : PubMed/NCBI
29	Lima Queiroz A, Zhang B, Comstock DE, Hao Y, Eriksson M, Hydbring P, Vakifahmetoglu-Norberg H and Norberg E: miR-126-5p targets malate dehydrogenase 1 in non-small cell lung carcinomas. Biochem Biophys Res Commun. 499:314–320. 2018. View Article : Google Scholar : PubMed/NCBI
30	Karagur ER, Ozay C, Mammadov R and Akca H: Anti-invasive effect of Cyclamen pseudibericum extract on A549 non-small cell lung carcinoma cells via inhibition of ZEB1 mediated by miR-200c. J Nat Med. 72:686–693. 2018. View Article : Google Scholar : PubMed/NCBI
31	Ali MA, Matboli M, El-Khazragy N, Saber O, El-Nakeep S, Abdelzaher HM, Shafei AE and Mostafa R: Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma. Biomark Med. 12:245–256. 2018. View Article : Google Scholar : PubMed/NCBI
32	Gómez de Cedrón M, Acín Pérez R, Sánchez-Martínez R, Molina S, Herranz J, Feliu J, Reglero G, Enríquez JA and Ramírez de Molina A: MicroRNA-661 modulates redox and metabolic homeostasis in colon cancer. Mol Oncol. 11:1768–1787. 2017. View Article : Google Scholar : PubMed/NCBI
33	Lara-Gonzalez P, Scott MI, Diez M, Sen O and Taylor SS: BubR1 blocks substrate recruitment to the APC/C in a KEN-box-dependent manner. J Cell Sci. 124:4332–4345. 2011. View Article : Google Scholar : PubMed/NCBI
34	Rape M, Reddy SK and Kirschner MW: The processivity of multiubiquitination by the APC determines the order of substrate degradation. Cell. 124:89–103. 2006. View Article : Google Scholar : PubMed/NCBI
35	Townsley FM, Aristarkhov A, Beck S, Hershko A and Ruderman JV: Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UBCH10 blocks cells in metaphase. Proc Natl AcadSci USA. 94:2362–2367. 1997. View Article : Google Scholar
36	Patel D and McCance DJ: Compromised spindle assembly checkpoint due to altered expression of UBCH10 and Cdc20 in human papillomavirus type 16 E6- and E7-expressing keratinocytes. J Virol. 84:10956–10964. 2010. View Article : Google Scholar : PubMed/NCBI